Interferon-induced pulmonary sarcoidosis.
A further new case of sarcoidosis associated with the use of interferon (IFN) in the classical treatment of chronic hepatitis C (CHC) is reported. During the last two years, more than 20 cases of interferon-induced sarcoidosis have been described in the literature and about half of these cases have involved CHC. Therefore this disorder appears more common than originally thought two years ago, possibly due to the more frequent use of interferon therapy and an improvement in the methods of diagnosis.
Farah
R
R
Department of Internal Medicine F, Western Galilee Hospital, RO.Box 21, Nahariya 22100, Israel. raymond_farah@yahoo.com
Farah
R
R
Makhoul
N
N
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D018893:Bronchoalveolar Lavage; D016516:CD4-CD8 Ratio; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D007964:Leukocytosis; D008218:Lymphocytosis; D008264:Macrophages / Q000276:immunology; D011994:Recombinant Proteins; D012129:Respiratory Function Tests; D012135:Respiratory Sounds; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced* / Q000503:physiopathology
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins